Regulatory updates (digest-only, lower relevance)
- (57) [regulations.gov] Importer of Controlled-Bright Green(2024-20083)DEA1426
- (57) [regulations.gov] Importer Controlled-VA Cooperative (2024-11795) DEA1374
- (48) [regulations.gov] Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
- (47) [regulations.gov] Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429
- (43) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
- (42) [regulations.gov] Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
- (38) [regulations.gov] Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I
- (38) [regulations.gov] Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I
- (35) [regulations.gov] Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I
- (35) [regulations.gov] Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.
- (35) [regulations.gov] Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I
- (35) [regulations.gov] Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)
- (35) [regulations.gov] Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
- (35) [regulations.gov] Schedules of Controlled Substances: Placement of Metonitazene in Schedule I
- (5) [regulations.gov] Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-F)
- (5) [regulations.gov] Medicare and Medicaid Programs; CY 2024 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Continued Implementation of Requirements for Manufacturers of Certain Single-dose Container or Single-use Package Drugs to Provide Refunds with Respect to Discarded Amounts; Medicare Advantage (CMS-1784-P)
- (2) [regulations.gov] Definition of Engaged in the Business as a Dealer in Firearms
Digest-Level Clinical Commentary
Clinical Reflection
These regulatory filings suggest ongoing DEA scrutiny of cannabis supply chain actors and continued federal scheduling activity around synthetic cannabinoid analogs, which indicates the agency remains focused on controlling novel compounds rather than de-scheduling cannabis itself. For my practice, this means I should maintain heightened documentation of patient cannabis sourcing and educate patients that federal scheduling inconsistencies may affect product availability and clinical guidance evolving unpredictably. The apparent emphasis on importer compliance and synthetic compound classification doesn’t materially change current evidence-based cannabis dosing or indication selection, but reinforces that legal status remains unstable despite growing medical literature supporting certain applications.
Clinical Perspective
These regulatory updates reflect ongoing DEA efforts to manage controlled substance importation and scheduling, including monitoring of novel synthetic compounds. The temporary placement actions indicate continued surveillance of emerging designer drugs that may have abuse potential. From a clinical standpoint, these regulatory changes underscore the importance of staying informed about controlled substance scheduling as new compounds enter the market and may present to emergency or addiction medicine settings.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: